CagriSema et Tirzépatide pour le diabète de type 2 sous Metformine

Cagrilintide

Semaglutide

Tirzepatide

Change in glycated haemoglobin (HbA1c)

Relative change in body weight

Change in HbA1c

Change in fasting plasma glucose (FPG)

Achievement of HbA1c target values of less than (<) 7.0% (<53 millimole per mole [mmol/mol])

Achievement of HbA1c target values of less than or equal to (≤) 6.5% (≤ 48 mmol/mol)

Achievement of greater than or equal to (≥) 5% weight reduction

Achievement of ≥ 10% weight reduction

Achievement of ≥ 15 % weight reduction

Achievement of ≥ 20 % weight reduction

Change in systolic blood pressure

Change in diastolic blood pressure

Change in waist circumference

Ratio to baseline in lipids: Total cholesterol

Ratio to baseline in lipids: High-density lipoprotein (HDL) cholesterol

Ratio to baseline in lipids: Low-density lipoprotein (LDL) cholesterol

Ratio to baseline in lipids: Very low-density lipoprotein (VLDL) cholesterol

Ratio to baseline in lipids: Triglycerides

Ratio to baseline in lipids: non-HDL cholesterol

Change From Baseline in Short Form-36 Version 2 (SF-36v2) (Acute Version) Health Survey

Change in Impact of Weight on Quality of Life-Lite Clinical Trials (IWQOL-Lite-CT) version 3

Number of Treatment-emergent Adverse Events (TEAEs)

Number of clinically significant hypoglycaemic episodes (level 2) (<3.0 mmol/L (<54 milligram per deciliter [mg/dL]), confirmed by blood glucose meter)

Number of severe hypoglycaemic episodes (level 3): hypoglycaemia associated with severe cognitive impairment requiring external assistance for recovery, with no specific glucose threshold